Orexigen, Takeda sue Actavis over generic Contrave

Orexigen Therapeutics Inc. (NASDAQ:OREX) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) filed suit in the U.S. District Court for the District of Delaware alleging that an ANDA submitted by Actavis plc (NYSE:ACT) for a generic version of obesity drug Contrave naltrexone/ bupropion infringes seven patents covering Contrave. Takeda has North American rights to the drug, which FDA approved in September 2014.

Orexigen and Takeda are seeking declaratory judgment that Actavis' generic version of Contrave infringes U.S. Patents Nos. 7,375,111; 7,462,626; 8,088,786; 8,318,788; 8,722,085; 8,815,889; and 8,916,195. They are also seeking a permanent injunction and monetary relief for damages. ...